MYERS INDUSTRIES INCMYEEarnings & Financial Report

NYSE · pharmaceutical industry

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid ...

Revenue

$205.4M

Gross Profit

$68.6M

Operating Profit

$17.7M

Net Profit

$7.1M

Gross Margin

33.4%

Operating Margin

8.6%

Net Margin

3.5%

YoY Growth

0.2%

EPS

$0.19

Financial Flow

MYERS INDUSTRIES INC Q3 2025 Financial Summary

MYERS INDUSTRIES INC reported revenue of $205.4M for Q3 2025, with a net profit of $7.1M (3.5% margin). Cost of goods sold was $136.9M, operating expenses totaled $50.9M.

Key Financial Metrics

Total Revenue	$205.4M
Net Profit	$7.1M
Gross Margin	33.4%
Operating Margin	8.6%
Report Period	Q3 2025

MYERS INDUSTRIES INC Annual Revenue by Year

MYERS INDUSTRIES INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $836.3M).

Year	Annual Revenue
2024	$836.3M
2023	$813.1M
2022	$899.5M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$191.1M	$207.1M	$220.2M	$205.1M	$203.9M	$206.8M	$209.6M	$205.4M
YoY Growth	-10.2%	-4.0%	5.7%	3.7%	6.7%	-0.2%	-4.8%	0.2%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$541.6M	$947.1M	$951.6M	$905.0M	$860.8M	$883.8M	$862.7M	$864.1M
Liabilities	$248.8M	$655.5M	$657.1M	$629.4M	$583.3M	$606.4M	$578.1M	$577.4M
Equity	$292.8M	$291.7M	$294.6M	$275.6M	$277.5M	$277.4M	$284.6M	$286.6M